secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001737287-24-000046
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit
--------------------------------------------------------------------------------

- JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).
- Overland's ownership in JV increases to 69.63%; Allogene's drops to 15.37% after share incentive plan increase.
- Exclusive license royalty changed to flat mid single-digit on net sales in territory, no longer subject to reductions.
- Allogene gains termination rights for funding default or failure to initiate tech transfer; license auto-terminates if Allogene's ownership <7.5% unless mutual plan agreed.
- Overland distributes all JV shares to HH BioPharma Holdings (HBP), which gets 3 of 5 board seats.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000046/0001737287-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000046/allo-20240524.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer